Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Tharimmune Inc

Clinical trials sponsored by Tharimmune Inc, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New strip drug targets debilitating itch in rare liver disease Results expected Mar 2027 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 1

New strip drug targets debilitating itch in rare liver disease

Symptom relief Not yet recruiting

This Phase 2a trial tests TH104, a nalmefene strip placed inside the cheek, for moderate to severe itching in primary biliary cholangitis (PBC). About 40 adults with PBC will receive either TH104 or a placebo to see if it safely reduces itch. The study is not yet recruiting.

Phase 2 • Sponsor: Tharimmune Inc • Aim: Symptom relief

Last updated Jun 26, 2026 15:06 UTC